Switch theme
Sign up to access all valuation multiples
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
2016
32
LTM Revenue n/a
LTM EBITDA n/a
-$91.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
I-MAB has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, I-MAB achieved revenue of n/a and an EBITDA of -$49.2M.
I-MAB expects next 12-month revenue of XXX and NTM EBITDA of XXX
See I-MAB valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.9M | n/a | XXX | XXX | XXX |
| Gross Profit | -$36.1M | $3.9M | XXX | XXX | XXX |
| Gross Margin | -925% | Infinity% | XXX | XXX | XXX |
| EBITDA | -$199M | -$49.2M | XXX | XXX | XXX |
| EBITDA Margin | -5109% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$363M | -$207M | XXX | XXX | XXX |
| Net Margin | -9319% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, I-MAB's stock price is $1.
I-MAB has current market cap of $77.9M, and EV of -$91.6M.
See I-MAB trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$91.6M | $77.9M | XXX | XXX | XXX | XXX | $-0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, I-MAB has market cap of $77.9M and EV of -$91.6M.
I-MAB's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate I-MAB's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for I-MAB and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$91.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 1.9x | XXX | XXX | XXX |
| P/E | -3.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpI-MAB's NTM/LTM revenue growth is n/a
I-MAB's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.6M for the same period.
Over next 12 months, I-MAB's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate I-MAB's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for I-MAB and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -75% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
I-MAB acquired XXX companies to date.
Last acquisition by I-MAB was XXXXXXXX, XXXXX XXXXX XXXXXX . I-MAB acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was I-MAB founded? | I-MAB was founded in 2016. |
| Where is I-MAB headquartered? | I-MAB is headquartered in United States of America. |
| How many employees does I-MAB have? | As of today, I-MAB has 32 employees. |
| Who is the CEO of I-MAB? | I-MAB's CEO is Dr. Xi-Yong Sean Fu. |
| Is I-MAB publicy listed? | Yes, I-MAB is a public company listed on NAS. |
| What is the stock symbol of I-MAB? | I-MAB trades under IMAB ticker. |
| When did I-MAB go public? | I-MAB went public in 2020. |
| Who are competitors of I-MAB? | Similar companies to I-MAB include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of I-MAB? | I-MAB's current market cap is $77.9M |
| Is I-MAB profitable? | Yes, I-MAB is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
